Infections caused by sensitive to the medication microorganisms: respiratory tract infections (including pneumonia in patients with cystic fibrosis); infections in patients with reduced immunity; skin and soft tissue infections; infections of ENT-organs; urinary tract infection; bacteremia, septicemia; bone and joint infections; infections of the gastrointestinal tract, biliary tract, and abdominal cavity; infections associated with hemo – and peritoneal dialysis and continuous outpatient peritoneal dialysis.Infections caused by sensitive to the medication microorganisms: respiratory tract infections (including pneumonia in patients with cystic fibrosis); infections in patients with reduced immunity; skin and soft tissue infections; infections of ENT-organs; urinary tract infection; bacteremia, septicemia; bone and joint infections; infections of the gastrointestinal tract, biliary tract, and abdominal cavity; infections associated with hemo – and peritoneal dialysis and continuous outpatient peritoneal dialysis.
active substance: ceftazidime;
1 vial contains ceftazidime (in the form of ceftazidime pentahydrate) 1.0 g;
Excipient: sodium carbonate anhydrous.
Evrozidim Dosage form
Powder for injection.
Main physical and chemical properties: white or pale yellow powder.
Antibacterial agents for systemic use. Cephalosporins. ATX code J01D D02.
Ceftazidime is a bactericidal cephalosporin antibiotic, the mechanism of action of which is associated with impaired synthesis of bacterial cell walls. Has a high activity against a wide range of gram-positive and gram-negative bacteria, including strains resistant to gentamicin and other aminoglycosides. Very resistant to most β-lactamases produced by both gram-positive and gram-negative microorganisms. Ceftazidime has high in vitro activity and acts within a narrow MIC range (minimum inhibitory concentration) against most infectious agents. In vitro studies with the drug in combination with aminoglycoside antibiotics had an additive effect, and in experiments with some strains, synergism was reported.
In an in vitro study, ceftazidime was shown to be active against such microorganisms.
Acquired antibiotic resistance varies from region to region and may change over time, and may differ significantly for individual strains. It is advisable to use local data on antibiotic susceptibility, especially in the treatment of severe infections.
Treatment of the following infections in adults and children, including newborns:
respiratory tract infections in patients with cystic fibrosis;
chronic otitis media;
malignant otitis externa;
complicated urinary tract infections;
complicated skin and soft tissue infections;
complicated infections of the abdominal cavity;
bone and joint infections;
peritonitis associated with dialysis in patients on continuous outpatient peritoneal dialysis.
Treatment of bacteremia that occurs in patients as a result of any of the above infections.
Ceftazidime can be used to treat patients with neutropenia and fever caused by a bacterial infection.
Ceftazidime can be used to prevent urinary tract infections during prostate surgery (transurethral resection).
When prescribing ceftazidime should take into account its antibacterial spectrum, directed mainly against gram-negative aerobes (see sections “Peculiarities” and “Pharmacological properties”).
Ceftazidime should be used with other antibacterial agents if a number of the microorganisms that caused the infection are not expected to fall within the spectrum of action of ceftazidime.
The drug should be prescribed in accordance with the existing official recommendations for the appointment of antibacterial agents.
Hypersensitivity to ceftazidime or to other components of the drug.
Hypersensitivity to cephalosporin antibiotics.
Presence of a history of severe hypersensitivity (eg, anaphylactic reactions) to other beta-lactam antibiotics (penicillins, monobactams, and carbapenems).